<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-20 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-20</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-20</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-1.html">extraction-schema-1</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <p><strong>Paper ID:</strong> paper-07fff1c9d77fb2b8731d7d86b38c7ac05df654c7</p>
                <p><strong>Paper Title:</strong> <a href="https://www.semanticscholar.org/paper/07fff1c9d77fb2b8731d7d86b38c7ac05df654c7" target="_blank">Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.</a></p>
                <p><strong>Paper Venue:</strong> Journal of the American Medical Association (JAMA)</p>
                <p><strong>Paper TL;DR:</strong> The Lung Cancer Mutation Consortium was formed to perform multiplexed assays testing adenocarcinomas of the lung for drivers in 10 genes to enable clinicians to select targeted treatments and enroll patients into clinical trials.</p>
                <p><strong>Cost:</strong> 0.02</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e20.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e20.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>EGFR(s)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>EGFR sensitizing mutations (exon 19 deletions, L858R, L861Q, G719X)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Canonical activating EGFR mutations known to sensitize lung adenocarcinomas to EGFR tyrosine kinase inhibitors (examples: exon 19 deletions, L858R, L861Q, G719X); detected and acted upon in this study.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>EGFR sensitizing mutations (exon 19 deletion, L858R, L861Q, G719X)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>point mutations / small in-frame deletions (activating mutations)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>EGFR (receptor tyrosine kinase) / RTK → RAS/RAF/MAPK and PI3K pathways</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>17% (122/733; full genotyping)</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>multiplex genomic profiling (targeted assays) in clinical tumor specimens; clinical response to EGFR TKIs (treatment data in cohort: 146/175 patients with EGFR(s) received targeted therapy)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>Clinical sensitivity to EGFR TKIs (erlotinib and other EGFR inhibitors) demonstrated in this cohort and referenced prior literature supporting oncogenic/driver role</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Associated with sensitivity to EGFR TKIs; historically enriched in never-smokers (paper references prior literature noting EGFR mutations common in never-smokers)</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>Approved targeted therapy available (EGFR TKIs such as erlotinib); used to select genotype-directed therapy in this study</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>Full genotyping cohort n = 733 (also 1007 had any genotyping)</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Targeted multiplex genotyping platforms (Sequenom MALDI-TOF, SNaPshot, Sanger with PNA probes); sizing electrophoresis used for EGFR deletions</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.', 'publication_date_yy_mm': '2014-05'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e20.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e20.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>EGFR(o)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>EGFR other mutations (exon 20 insertions, de novo T790M, other non-sensitizing EGFR changes)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>EGFR mutations not typically associated with sensitivity to first-generation EGFR TKIs, including exon 20 insertions and de novo T790M; identified in the cohort and reported separately from sensitizing EGFR mutations.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>EGFR exon 20 insertions, de novo T790M, and other non-sensitizing EGFR mutations</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>small insertions / point mutations (activating or resistance-associated alterations)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>EGFR (receptor tyrosine kinase)</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>4% (29/733; full genotyping) — includes 18 exon 20 insertions, 7 de novo T790M, 4 other</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>multiplex genomic profiling; clinical annotation of treatments (some patients with EGFR(o) still received EGFR inhibitors / other targeted agents)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>Not functionally demonstrated in this paper; prior literature cited on exon 20 insertions and their differing sensitivity profile to EGFR TKIs</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Reported separately due to different expected drug sensitivity; some patients with EGFR(o) received EGFR inhibitors or other targeted therapy in this cohort</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>Typically less sensitive to standard EGFR TKIs; some patients were treated with EGFR inhibitors or other targeted agents/trials (23/35 in any-genotyping group received some targeted therapy)</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>Full genotyping cohort n = 733</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Sizing electrophoresis for EGFR deletions and targeted mutational assays (Sequenom, SNaPshot, Sanger)</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.', 'publication_date_yy_mm': '2014-05'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e20.2">
                <h3 class="extraction-instance">Extracted Data Instance 2 (e20.2)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>ALK</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>ALK rearrangements (gene fusions, e.g., EML4-ALK)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>ALK gene rearrangements producing oncogenic fusions were tested by FISH and identified as actionable drivers; patients with ALK rearrangements frequently received crizotinib in the study.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>ALK gene rearrangement / fusion (e.g., EML4-ALK referenced)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>gene fusion / structural rearrangement</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>ALK (receptor tyrosine kinase) / RTK → downstream signaling including RAS/RAF/MAPK</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>8% (57/733; full genotyping)</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>FISH-based genomic profiling (ALK FISH); clinical response to ALK inhibitor (crizotinib) in treated patients (52/80 overall ALK+ patients treated in any-genotyping group)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>Clinical responses to ALK inhibitor therapy reported in this cohort and prior literature support the oncogenic role of ALK fusions</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Identified as a distinct actionable subset; cohort-level survival shown for ALK-positive patients (median survival ~4.25 years)</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>Crizotinib (ALK inhibitor) used as matched targeted therapy; actionable and included in treatment selection</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>Full genotyping cohort n = 733 (ALK tested by FISH in sites)</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Fluorescence in situ hybridization (FISH) for ALK rearrangements; referenced prior molecular studies</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.', 'publication_date_yy_mm': '2014-05'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e20.3">
                <h3 class="extraction-instance">Extracted Data Instance 3 (e20.3)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>KRAS</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>KRAS mutations (oncogenic RAS)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>KRAS point mutations were the most frequent single-gene driver detected in the cohort; historically common and often considered a canonical RAS-pathway driver but lacked approved targeted therapies at time of study.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>KRAS mutations (various codons; oncogenic point mutations)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>point mutation (activating RAS mutations)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>KRAS (RAS family) / RAS → RAF → MEK → ERK pathway</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>25% (182/733; full genotyping)</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>targeted mutational profiling (Sequenom/SNaPshot/Sanger); referenced biological/therapeutic literature; a subset enrolled on investigational targeted agents (22 patients with KRAS mutations received investigational agents)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Most frequent driver in cohort; past literature associates KRAS with smoking-related tumors (paper references relevant studies)</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>No approved targeted therapy in this study; some patients enrolled on investigational targeted agents (22 patients)</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>Full genotyping cohort n = 733</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Targeted multiplex mutational assays (Sequenom MALDI-TOF, SNaPshot, Sanger)</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.', 'publication_date_yy_mm': '2014-05'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e20.4">
                <h3 class="extraction-instance">Extracted Data Instance 4 (e20.4)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>ERBB2</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>ERBB2 (HER2) exon 20 insertions</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>ERBB2 (formerly HER2) exon 20 insertions were detected as actionable albeit less frequent drivers; patients with these mutations were enrolled on ERBB2-targeted trials in some cases.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>ERBB2 (HER2) exon 20 insertion mutations</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>small in-frame insertions (activating)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>ERBB2 / HER2 (receptor tyrosine kinase) / RTK → downstream signaling</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>3% (19/733; full genotyping)</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>targeted genomic profiling (sizing electrophoresis and mutation assays); clinical trial enrollment (11/23 ERBB2-mutant patients received ERBB2-targeted agent in any-genotyping group)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Detected as a distinct subset (all were exon 20 insertions per the study); considered actionable and led to trial enrollment</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>ERBB2-targeted agents used in trials for patients with these mutations (some treated in cohort)</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>Full genotyping cohort n = 733</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Sizing electrophoresis for exon 20 insertions; targeted mutational assays</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.', 'publication_date_yy_mm': '2014-05'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e20.5">
                <h3 class="extraction-instance">Extracted Data Instance 5 (e20.5)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>BRAF</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>BRAF mutations (V600E and non-V600E)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>BRAF point mutations, including V600E and non-V600E variants, were identified at low frequency and some patients were treated with BRAF inhibitors.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>BRAF mutations (including V600E and non-V600E variants)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>point mutations (activating kinase mutations)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>BRAF (RAF family) / RAS/RAF/MEK/ERK pathway</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>2% (16/733; full genotyping) — V600E: 12/733 (~1.6%), non-V600E: 4/733 (~0.5%)</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>targeted genomic profiling; some patients received BRAF inhibitors (3/18 in any-genotyping group received targeted therapy)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>Clinical application in some patients (BRAF inhibitors administered); no new functional experiments reported in this paper</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>BRAF inhibitors available/used in trials for BRAF-mutant patients; treated patients identified in cohort</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>Full genotyping cohort n = 733</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Targeted mutational assays (Sequenom/SNaPshot/Sanger)</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.', 'publication_date_yy_mm': '2014-05'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e20.6">
                <h3 class="extraction-instance">Extracted Data Instance 6 (e20.6)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>PIK3CA</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>PIK3CA mutations</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>PIK3CA point mutations were identified at very low frequency in the cohort, and frequently co-occurred with other drivers (noted in doubleton cases).</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>PIK3CA point mutations</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>point mutation (activating variants in PI3K catalytic subunit)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>PIK3CA / PI3K → AKT pathway (PI3K-AKT signaling)</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>≈0.8% (6/733; full genotyping)</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>targeted genomic profiling; observed co-occurrence with other drivers (noted in doubletons: 12 of 20 doubletons involved PIK3CA in one report)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Often co-occurred with other drivers in doubleton tumors (paper notes PIK3CA co-occurrence in many doubletons)</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>No patients with PIK3CA mutations in this cohort received a targeted therapy (0 treated in any-genotyping group)</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>Full genotyping cohort n = 733</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Targeted mutational assays (Sequenom/SNaPshot/Sanger)</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.', 'publication_date_yy_mm': '2014-05'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e20.7">
                <h3 class="extraction-instance">Extracted Data Instance 7 (e20.7)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>MET amp</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>MET amplification (copy number gain)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>MET gene amplification (MET/CEP7 > 2.2) was detected infrequently by FISH and in some cases co-occurred with other drivers; a subset of MET-amplified patients received MET-targeted therapy.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>MET amplification (copy number gain; MET/CEP7 > 2.2)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>gene amplification / copy number alteration</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>MET (receptor tyrosine kinase) / RTK → downstream signaling including RAS/RAF and PI3K pathways</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td><1% (5/733; full genotyping)</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>FISH-based copy number assessment; noted co-occurrence with other drivers in doubletons (8 MET amplifications noted among doubletons in aggregated counts)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Observed in small number of cases; included among doubletons in multiple cases</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>MET-targeted agents/trials available; 3/6 MET-amplified patients in any-genotyping group received targeted therapy</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>Full genotyping cohort n = 733</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Fluorescence in situ hybridization (FISH) for MET amplification</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.', 'publication_date_yy_mm': '2014-05'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e20.8">
                <h3 class="extraction-instance">Extracted Data Instance 8 (e20.8)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>NRAS</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>NRAS mutations</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>NRAS point mutations were identified rarely in lung adenocarcinomas in this cohort (very low frequency).</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>NRAS point mutations</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>point mutation (activating RAS family mutations)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>NRAS (RAS family) / RAS → RAF → MEK pathway</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td><1% (5/733; full genotyping)</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>targeted genomic profiling (detected by multiplex assays); referenced literature on NRAS characteristics</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>No patients with NRAS mutations in this cohort received targeted therapy (0 treated in any-genotyping group)</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>Full genotyping cohort n = 733</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Targeted mutational assays (Sequenom/SNaPshot/Sanger)</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.', 'publication_date_yy_mm': '2014-05'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e20.9">
                <h3 class="extraction-instance">Extracted Data Instance 9 (e20.9)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>MEK1</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>MEK1 (MAP2K1) mutations</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>MEK1 mutations were very rarely identified (only a single MEK1 mutation detected in full-genotyping cohort).</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>MEK1 (MAP2K1) point mutation(s)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>point mutation (activating in MAP kinase kinase)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>MEK1 / MAP2K1 (part of RAS/RAF/MEK/ERK pathway)</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td><1% (1/733; full genotyping)</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>targeted genomic profiling (detected by multiplex assays)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>No patients with MEK1 mutation in this cohort received targeted therapy (0 treated in full-genotyping group)</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>Full genotyping cohort n = 733</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Targeted mutational assays (Sequenom/SNaPshot/Sanger)</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.', 'publication_date_yy_mm': '2014-05'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e20.10">
                <h3 class="extraction-instance">Extracted Data Instance 10 (e20.10)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>AKT1</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>AKT1 mutations</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>AKT1 mutations were assayed but none were detected in the fully genotyped cohort.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>AKT1 point mutations (none detected in full-genotyping cohort)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>point mutation</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>AKT1 / PI3K-AKT pathway</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>0% (0/733; full genotyping)</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>targeted genomic profiling (no detections)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>Full genotyping cohort n = 733</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Targeted mutational assays (Sequenom/SNaPshot/Sanger)</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.', 'publication_date_yy_mm': '2014-05'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e20.11">
                <h3 class="extraction-instance">Extracted Data Instance 11 (e20.11)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Doubletons</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Co-occurring oncogenic drivers (tumors with >1 driver)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A small subset of tumors harbored oncogenic alterations in two genes; many doubletons included PIK3CA mutations or MET amplification co-occurring with another driver.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>Co-occurrence of two oncogenic genomic changes in the same tumor (e.g., PIK3CA + another driver; MET amplification + another driver)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>multiple (co-occurring) alterations including point mutations and amplifications</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>Various (frequently PIK3CA or MET co-occurring with other drivers)</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>3% (24/733; full genotyping had 24 doubletons; any-genotyping 27/1007)</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>multiplex genomic profiling (co-occurrence observed directly in sequencing/panel results)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Paper notes 20 of 24 doubletons included either PIK3CA (n=12) or MET amplification (n=8)</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>Physician discretion used to decide which driver to target; some doubleton patients received targeted agents (15/24 doubletons treated with targeted therapy)</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>Full genotyping cohort n = 733</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Targeted multiplex assays and FISH for amplification</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.', 'publication_date_yy_mm': '2014-05'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e20.12">
                <h3 class="extraction-instance">Extracted Data Instance 12 (e20.12)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>RET (mention)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>RET gene fusions (e.g., KIF5B-RET)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>RET fusions (KIF5B-RET and others) are mentioned as additional actionable fusions that have been added to LCMC panels after the study design; they were not part of the original 10-gene panel but are described as newly included targets.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>RET gene fusions (e.g., KIF5B-RET)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>gene fusion / rearrangement</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>RET (receptor tyrosine kinase) / RTK → downstream signaling</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>literature mention / panel expansion (paper cites external studies identifying RET fusions)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>RET fusions considered actionable and added to multiplex panels for trial selection (mentioned as now added)</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Not assayed in the original 10-gene panel in this study (later added to panels as noted); detection elsewhere by genomic fusion assays</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.', 'publication_date_yy_mm': '2014-05'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e20.13">
                <h3 class="extraction-instance">Extracted Data Instance 13 (e20.13)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>ROS1 (mention)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>ROS1 rearrangements / fusions</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>ROS1 gene rearrangements are mentioned as an additional rare actionable fusion class that has been added to multiplex testing panels; referenced as defining a unique molecular class of lung cancers.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>ROS1 gene rearrangement / fusion</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>gene fusion / structural rearrangement</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>ROS1 (receptor tyrosine kinase) / RTK → downstream signaling including RAS/RAF pathways</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>literature mention (paper cites prior work on ROS1 rearrangements)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>ROS1 fusions are targetable (external literature); noted as added to LCMC multiplex panels</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Not part of original 10-gene panel in this study; generally detected by FISH or fusion assays elsewhere</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.', 'publication_date_yy_mm': '2014-05'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>New driver mutations in non-small cell lung cancer <em>(Rating: 2)</em></li>
                <li>A genomics-based classification of human lung tumors <em>(Rating: 2)</em></li>
                <li>Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing <em>(Rating: 2)</em></li>
                <li>Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas <em>(Rating: 2)</em></li>
                <li>KIF5B-RET fusions in lung adenocarcinoma <em>(Rating: 2)</em></li>
                <li>ROS1 rearrangements define a unique molecular class of lung cancers <em>(Rating: 2)</em></li>
                <li>Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations <em>(Rating: 1)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>